RecruitingNot ApplicableNCT07394608

Paired Non-invasive VNS in Adolescent Cerebral Palsy Rehabilitation

Use of Paired Non-Invasive Vagus Nerve Stimulation in Rehabilitation of Adolescents With Cerebral Palsy: An Open Label Safety Feasibility Trial


Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

10 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is an open-label safety and feasibility trial evaluating the use of paired non-invasive vagus nerve stimulation (VNS) and upper extremity (UE) rehabilitation in the motor impairment reduction of adolescent patients with spastic cerebral palsy.


Eligibility

Min Age: 12 YearsMax Age: 17 Years

Inclusion Criteria6

  • Age 12-17 years old
  • Diagnosis of spastic cerebral palsy
  • Gross Motor Function Classification System (GMFCS) Level II-III (will be evaluated at screening)
  • Jebsen Taylor Hand Function Test Score of <37.08 on the affected side at time of screening visit (will be evaluated at screening)
  • Ability to communicate and follow two step commands at the time of screening
  • Ability to provide assent as detailed in consent form and based on assessment using the University of California, San Diego Brief Assessment of Capacity to Consent

Exclusion Criteria13

  • Previous vagus nerve injury
  • Less than 12 years old or greater than 18 years old
  • History of left or bilateral vagotomy
  • Current use of other implanted stimulation devices including but not limited to pacemaker, deep brain stimulator, implanted vagus nerve stimulators, cochlear implants, implantable cardiac defibrillators (ICDs)etc.
  • Current use of any investigational devices or investigational drugs not otherwise specified - Past Medical History for any of the following:
  • Acute suicidal thinking or behavior
  • History of schizophrenia, schizoaffective disorder, or delusional disorders
  • History of rapid cycling bipolar disorder
  • Progressive neurological diseases
  • Cardiac arrhythmias or other abnormalities
  • History of dysautonomia including but not limited to orthostatic hypotension, postural orthostatic tachycardia syndrome, vasovagal syncope etc.
  • GMFCS score of less than II or greater than III (will be evaluated at screening)
  • Jebsen Taylor Hand Function Test Score of >37.08 on the affected side at time of screening visit (will be evaluated at screening)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENon-invasive taVNS

Device activates the vagus through the ear. The device is controlled via the Vagustim mobile app, which connects using Bluetooth Low Energy (BLE).


Locations(1)

The Charles Lazarus Children's Abilities Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07394608


Related Trials